Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage As a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies
Overview
Authors
Affiliations
Background: Interstitial fibrosis and tubular atrophy (IFTA) associated with interstitial inflammation in nonscarred areas (IFTA+i) is associated with poorer graft outcome than inflammation without IFTA or IFTA without inflammation.
Methods: We evaluated if histological categories at week 6 could predict the development of interstitial fibrosis and de novo donor specific anti-HLA antibodies (dnDSA) at 1 year. Biopsies were classified according to Banff criteria as normal (i+t≤1 and ci+ct≤1), inflammation (i+t≥2 and ci+ct≤1), IFTA (i+t≤1 and ci+ct≥2) or IFTA+i (i+t≥2 and ci+ct≥2).
Results: We analyzed 598 standard immunological risk recipients. The histological diagnosis at 6 weeks was: normal (n = 206), inflammation (n = 29), IFTA (n = 255), and IFTA+i (n = 108). Moderate/severe interstitial fibrosis (ci≥2) at 1 year was observed in 4.2% of patients with prior (6 weeks) normal histology, in 3.4% with inflammation, in 13.8% with IFTA, and in 24.5% with IFTA+i (P = 0.0001). Fifty-three recipients (8.9%) had dnDSA at 1 year. Independent predictors of development of dnDSA at 1 year were: HLA-DR mismatches (odds ratio [OR], 1.95; 95% confidence interval [95% CI], 1.09-3.49), the presence of inflammation (OR, 5.49; 95% CI, 1.67-18.03) or IFTA+i (OR, 4.09; 95% CI, 1.67-10.0) in the 6-week surveillance biopsy.
Conclusions: Early subclinical inflammation in surveillance biopsies with or without tubulointerstitial chronic lesions is associated with an increased risk of dnDSA development.
Delayed Graft Function and the Renin-angiotensin System.
Yamani F, Cianfarini C, Batlle D Transplantation. 2024; 108(6):1308-1318.
PMID: 38361243 PMC: 11136607. DOI: 10.1097/TP.0000000000004934.
Rodrigo E, Quintana L, Vazquez-Sanchez T, Sanchez-Fructuoso A, Buxeda A, Gavela E Clin Kidney J. 2024; 17(1):sfad259.
PMID: 38186867 PMC: 10768752. DOI: 10.1093/ckj/sfad259.
Heldal T, Asberg A, Ueland T, Reisaeter A, Pischke S, Mollnes T Front Immunol. 2023; 14:1253991.
PMID: 37849758 PMC: 10577420. DOI: 10.3389/fimmu.2023.1253991.
Hernandez D, Vazquez-Sanchez T, Sola E, Lopez V, Ruiz-Esteban P, Caballero A BMC Nephrol. 2022; 23(1):357.
PMID: 36344929 PMC: 9639260. DOI: 10.1186/s12882-022-02989-z.
Seron D, Rabant M, Becker J, Roufosse C, Bellini M, Bohmig G Transpl Int. 2022; 35:10135.
PMID: 35669975 PMC: 9163314. DOI: 10.3389/ti.2022.10135.